Cargando…

Effects of concomitant use of prasugrel with edoxaban on bleeding time, pharmacodynamics, and pharmacokinetics of edoxaban in healthy elderly Japanese male subjects: a clinical pharmacology study

BACKGROUND: Dual therapy with a direct oral anticoagulant (DOAC) plus a P2Y(12) receptor inhibitor is recommended in patients with nonvalvular atrial fibrillation who undergo percutaneous coronary intervention. Thus, we evaluated the effects of DOAC edoxaban plus P2Y(12) receptor inhibitor prasugrel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ikushima, Ippei, Akasaka, Takaaki, Morishima, Yoshiyuki, Takita, Atsushi, Motohashi, Tomoko, Kimura, Tetsuya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291522/ https://www.ncbi.nlm.nih.gov/pubmed/32536828 http://dx.doi.org/10.1186/s12959-020-00223-0

Ejemplares similares

Sensory evaluation of edoxaban orally disintegrating tablets: an open-label interventional study (secondary publication)
por: Yamashita, Takeshi, et al.
Publicado: (2019)

Plasma Concentration and Pharmacodynamics of Edoxaban in Patients with Nonvalvular Atrial Fibrillation and Acute Heart Failure
por: Nabeta, Takeru, et al.
Publicado: (2021)

Edoxaban: Minor bleeding: case report
Publicado: (2022)

Evaluation of the Pharmacokinetics and Pharmacodynamics of Prasugrel in Japanese Elderly Subjects
por: Hasunuma, Tomoko, et al.
Publicado: (2017)

Pharmacokinetics of anticoagulant edoxaban in overdose in a Japanese patient transported to hospital
por: Adachi, Koichiro, et al.
Publicado: (2020)

The Effect of Rifampin on the Pharmacokinetics of Edoxaban in Healthy Adults
por: Mendell, Jeanne, et al.
Publicado: (2015)

The Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Japanese Volunteers
por: Umemura, Kazuo, et al.
Publicado: (2016)

The edoxaban‐M4 metabolite and measurement of edoxaban by chromogenic assays in human plasma
por: Siriez, Romain, et al.
Publicado: (2022)

Factors associated with bleeding events during catheter ablation with uninterrupted periprocedural edoxaban for atrial fibrillation: a subanalysis of the KYU-RABLE study
por: Abe, Ichitaro, et al.
Publicado: (2021)

High incidence of major bleeding with off-label use of edoxaban
por: Fukui, Rika, et al.
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa
por: Parasrampuria, Dolly A., et al.
Publicado: (2015)

Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban
por: Bosch, Floris T. M., et al.
Publicado: (2021)

Prediction and Implications of Edoxaban-Associated Bleeding in Patients after Critical Illness
por: Mikami, Ryusei, et al.
Publicado: (2023)

Managing patients taking edoxaban in dentistry
por: Curto, Adrian, et al.
Publicado: (2017)

Physiologically‐based pharmacokinetic pharmacodynamic parent‐metabolite model of edoxaban to predict drug–drug‐disease interactions: M4 contribution
por: Xu, Ruijuan, et al.
Publicado: (2023)

The Edoxaban Hokusai VTE PEDIATRICS Study: An open‐label, multicenter, randomized study of edoxaban for pediatric venous thromboembolic disease
por: van Ommen, Cornelia Heleen, et al.
Publicado: (2020)

Hokusai-VTE: Edoxaban for the treatment of venous thromboembolism
por: Said, Karim
Publicado: (2013)

Edoxaban in venous thromboembolism and stroke prevention: an appraisal
por: Proietti, Marco, et al.
Publicado: (2016)

Diffuse Alveolar Hemorrhage Associated with Edoxaban Therapy
por: Nitta, Kenichi, et al.
Publicado: (2016)

Superior mesenteric vein thrombosis treated with edoxaban
por: Hashizume, Yutaka, et al.
Publicado: (2017)

Impact of Edoxaban on Thrombin-Dependent Platelet Aggregation
por: Sokol, Juraj, et al.
Publicado: (2020)

Use of Edoxaban for the Treatment of Heparin-Induced Thrombocytopenia
por: Kanamoto, Ryo, et al.
Publicado: (2020)

Rapid Assay for the Therapeutic Drug Monitoring of Edoxaban
por: Rashid, Md Abdur, et al.
Publicado: (2022)

Bleeding Risk and Mortality of Edoxaban: A Pooled Meta-Analysis of Randomized Controlled Trials
por: Li, Shuang, et al.
Publicado: (2014)

Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban
por: Benz, Alexander P., et al.
Publicado: (2022)

Clinical trial assessing the safety of edoxaban with concomitant chemotherapy in patients with gynecological cancer-associated thrombosis (EGCAT study)
por: Oride, Tadashi, et al.
Publicado: (2023)

Edoxaban, a direct oral factor Xa inhibitor, ameliorates coagulation, microvascular thrombus formation, and acute liver injury in a lipopolysaccharide-induced coagulopathy model in rats
por: Morishima, Yoshiyuki, et al.
Publicado: (2021)

Edoxaban treatment for pulmonary arterial thromboembolism associated with azygous vein aneurysm
por: Mochimaru, Takao, et al.
Publicado: (2017)

A randomized, open-label trial of edoxaban in Japanese patients with severe renal impairment undergoing lower-limb orthopedic surgery
por: Fuji, Takeshi, et al.
Publicado: (2015)

Risk impact of edoxaban in the management of stroke and venous thromboembolism
por: Hurst, Katherine V, et al.
Publicado: (2016)

Edoxaban drug–drug interactions with ketoconazole, erythromycin, and cyclosporine
por: Parasrampuria, Dolly A., et al.
Publicado: (2016)

Point-of-care testing of coagulation in patients treated with edoxaban
por: Härtig, Florian, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects
por: Parasrampuria, Dolly A., et al.
Publicado: (2015)

Changes in plasma concentrations of edoxaban and coagulation biomarkers according to thromboembolic risk and atrial fibrillation type in patients undergoing catheter ablation: Subanalysis of KYU‐RABLE
por: Shinohara, Tetsuji, et al.
Publicado: (2020)

Thrombosis in an Internal Jugular Vein and an Upper Limb Deep Vein Treated with Edoxaban
por: Toratani, Mizuho, et al.
Publicado: (2017)

Effect of the number of dose adjustment factors on bleeding risk in patients receiving 30 mg/day edoxaban
por: Takase, Tomoki, et al.
Publicado: (2019)

Association between SLCO1B1 genetic polymorphisms and bleeding risk in patients treated with edoxaban
por: Han, Ji Min, et al.
Publicado: (2023)

Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor
por: Bounameaux, Henri, et al.
Publicado: (2014)

Evaluation of regional gastrointestinal absorption of edoxaban using the enterion capsule
por: Parasrampuria, Dolly A., et al.
Publicado: (2015)

Comparative risk impact of edoxaban in the management of stroke and venous thromboembolism
por: Tellor, Katie B, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ie4jf361pe9r207slhsu1bgan1